Management of chemo/radiation-induced oral mucositis in patients with head and neck cancer: A review of the current literature.
Dariush Moslemi, Akram Mohammadi Nokhandani, Mahsa Taheri Otaghsaraei...
https://pubmed.ncbi.nlm.nih.gov/27113797/Actively Recruiting
Led by First Affiliated Hospital of Guangxi Medical University · Updated on 2024-08-07
190
Participants Needed
20
Research Sites
100 weeks
Total Duration
This research aims to assess whether immunonutrition can reduce oral mucositis compared with standard nutrition in patients with locally advanced nasopharyngeal carcinoma receiving chemoradiotherapy. Oral mucositis is a common and severe side effect in these patients, causing pain, difficulty swallowing, and malnutrition, which can disrupt treatment and worsen quality of life and prognosis. Nutritional interventions like immunonutrition may help improve immune response, reduce inflammation, and enhance treatment tolerance and outcomes. Participants receive induction chemotherapy with gemcitabine and cisplatin followed by concurrent chemoradiotherapy with intensity-modulated radiotherapy and cisplatin. They are randomly assigned to one of two groups one group receives enteral immunonutrition Oral Impact twice daily starting 5 days before radiotherapy until treatment ends, while the other group receives a standard enteral nutrition formula ENSURE three times daily over the same period. During the study, participants are monitored for the incidence, timing, and duration of severe oral mucositis over 7 weeks. Researchers also assess immune status, inflammatory markers, nutritional and physical function, quality of life, and survival rates up to 2 years after randomization. Safety and adverse events are recorded throughout the study. Participants are expected to follow scheduled visits, laboratory tests, and questionnaires.
CONDITIONS
Effect of Immunonutrients on Oral Mucositis in Nasopharyngeal Carcinoma Patients After Chemoradiotherapy
Z
Zhen Meng, M.D
Y
Yating Qin, M.D
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
First Affiliated Hospital of Guangxi Medical University
Lead Sponsor
Guangdong Provincial People's Hospital
Collaborating Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Approximately 7 weeks
Participants receive induction chemotherapy followed by concurrent chemoradiotherapy. They also take either enteral immunonutrition or standard enteral nutrition starting 5 days before radiotherapy and continuing until the end of radiotherapy.
Multiple visits during chemotherapy and radiotherapy over 7 weeks
Duration - Up to 2 years after randomization
Participants are monitored for immune state, nutritional status, quality of life, and survival outcomes after completing treatment.
Periodic visits for assessments up to 2 years
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
SUPPORTIVE_CARE
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Dariush Moslemi, Akram Mohammadi Nokhandani, Mahsa Taheri Otaghsaraei...
https://pubmed.ncbi.nlm.nih.gov/27113797/Zhuangzhuang Zheng, Xin Zhao, Qin Zhao...
https://pubmed.ncbi.nlm.nih.gov/33598427/Rafi Kabarriti, Amanda Bontempo, Maria Romano...
https://pubmed.ncbi.nlm.nih.gov/29671062/Tanadech Dechaphunkul, Tippawan Arundon, Ponpis Raungkhajon...
https://pubmed.ncbi.nlm.nih.gov/35007812/Zekai Shu, Ziyi Zeng, Bingqi Yu...
https://pubmed.ncbi.nlm.nih.gov/33240818/Pierre Boisselier, Marie-Christine Kaminsky, Simon Thézenas...
https://pubmed.ncbi.nlm.nih.gov/32936874/J Talvas, G Garrait, N Goncalves-Mendes...
https://pubmed.ncbi.nlm.nih.gov/25575640/Leifeng Liang, Zhibing Liu, Haisheng Zhu...
https://pubmed.ncbi.nlm.nih.gov/34910297/Hiroshi Miyata, Masahiko Yano, Takushi Yasuda...
https://pubmed.ncbi.nlm.nih.gov/27644137/Chaofei Xia, Chunling Jiang, Wenyu Li...
https://pubmed.ncbi.nlm.nih.gov/33841399/First Affiliated Hospital of Guangxi Medical University
Lead Sponsor
Guangdong Provincial People's Hospital
Collaborating Sponsor